Market Newsdesk

AUSTIN, Texas, July 05, 2023 (GLOBE NEWSWIRE) — Volcon, Inc. (NASDAQ: VLCN) announced today that it provided key Department of Defense staff a demonstration of the all-electric Stag UTV and EVO motorcycles under the funded program Electric Tactical Humanitarian Operations Response, or eTHOR, hosted by the NavalX SoCal Tech Bridge at Marine Corps Tactical Systems Support Activity (MCTSSA), in Camp Pendleton, CA. This project was developed through the SoCal Tech Bridge’s ongoing relationship with Naval Information Warfare Center – Pacific (NIWC-PAC) to provide government evaluation and engagement with new technologies and with CANA LLC, serving as lead system integrator while providing modeling, simulation and analysis, and strategic stakeholder engagement. Working with Amazon Web Services (AWS), a subsidiary of Amazon.com Inc., and other integrators, the purpose of the demonstration and assessment was to test eTHOR functionality within a variety of military vignettes. Volcon demonstrated Level 3 fast charging, silent overwatch, night reconnaissance, and the ability to charge their EVO off-road motorcycle from a modified Stag UTV to exhibit power exporting capabilities. Data gathered will be used for continued modeling, simulation, and analysis, creating digital environments that synthesize the results of innumerable types of experimentation. The demonstration and testing event supports validation that there is a real, tested, and expeditious transition path for commercial integrated electric vehicle technology into the military operating environment.

“Volcon is proud to not only help electrify the battlefield, but also increase the range of tools the DoD can access and at the expedited pace we see in the commercial space,” mentioned Richard Tannery V.P. of Global Defense and Government Programs at Volcon. “We continue to show how capable we are to rapidly pivot toward the needs of our clients, which is instrumental for success in regards to search, rescue and defense operations. In less than a year we have sold several units to the US Army Corps of Engineers, answered multiple solicitations for electric vehicles, and now begin our journey into larger funded development programs to help advance future technologies by bridging commercial and government sectors,” Tannery continued.

The eTHOR prototype, a project funded by the Operational Energy Capability Improvement Fund (OECIF), is an integrated, electric, unmanned mobile power station built by DD DANNAR LLC; coupled with Innovation, Connectivity & Experimentation (ICE), provides a high speed, high bandwidth, low latency, 5G capable platform developed by AWS. eTHOR’s electric vehicle provides agility, traditional fuel independence, and the ability to store, transport and export power. Its communications capacities combine 5G, 4G LTE, SatCom, and mesh networking with secure cloud computing and forward edge processing. Will Berry, of CANA LLC, who leads the project management and strategic partnership efforts, had this to say: “The demonstration this week is a real validation of the vision, talents, and innovative efforts of the partners. It’s also a critical time to gather data for further testing and evaluation; we want to show how eTHOR can transform military operations in a tangible way. What’s exciting is that we’re not planning for some time in the future – eTHOR is here now.”

“The application of electrification doesn’t stop at civilian mobility. The benefits of EV technology are as applicable to the warfighter’s needs as they are to humanitarian relief efforts, especially considering technologies can be paired with our vehicles as a force multiplier in either scenario,” commented Jordan Davis, Volcon Chief Executive Officer. “We believe the possibilities to support our military, as well as the NGO community with mobility solutions, is only beginning. Our work with AWS and others on the eTHOR program will serve as a proof of concept of what we believe will be continued expansion into these new sectors.”

Also present during the week of live, onsite, demonstrations in June were eTHOR stakeholders from across the US Marine Corps, and commercial integrators from Athonet, Digital Force Technologies, Moxion, and Renewable Equipment. This is one example of the many applications for which electric vehicles are being used to explore opportunities outside of conventional public sector operations and contracts, expanding their pallet of tools and allowing for more rapid procurement for situations when it matters most.

About


Volcon, Inc

Based in the Austin, Texas area, Volcon was founded as the first all-electric powersports company producing high-quality and sustainable electric vehicles for the outdoor community. Volcon electric vehicles are the future of off-roading, not only because of their environmental benefits, but also because of their near silent operation, which allows for a more immersive outdoor experience.

Volcon’s 2023 vehicle roadmap includes both motorcycles and UTVs hitting the market in North America. Its first product, the innovative Grunt, has been shipping to customers since late 2021 and combines a fat-tired physique with high-torque electric power and a near-silent drive train. Volcon just announced the launch of the Grunt EVO, an evolution of the original Grunt with a belt drive, an improved suspension and seat. Volcon also just announced the launch of the Runt LT, which is a fun-sized version of the groundbreaking Grunt, is better suited for small statured riders, more compact properties and trails, or as a pit bike at race events, while still delivering robust off-road capabilities. The Brat is Volcon’s first foray into the wildly popular eBike market for both on road and off-road riding and is currently being delivered to dealers across North America. Volcon is also launching and currently delivering the Volcon Youth Line of dirt bikes for younger riders between the ages of 4 to 11. Volcon recently launched the Stag and entered the rapidly expanding UTV market. The Stag empowers the driver to explore the outdoors in a new and unique way that gas-powered UTVs cannot. The Stag offers the same thrilling performance of a standard UTV without the noise (or pollution), allowing the driver to explore the outdoors with all their senses.

Volcon Contacts:

For Media: [email protected]
For Dealers: [email protected]
For Investors: [email protected] 

Volcon Products:
Volcon Stag: https://www.volcon.com/stag
Volcon Brat: https://www.volcon.com/brat
Volcon Grunt: https://www.volcon.com/grunt-evo
Volcon Runt: https://www.volcon.com/runt-lt
Volcon Youth Line: https://www.volcon.com/youth

Forward-Looking Statements

Some of the statements in this release are forward-looking statements, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, whether the Company can begin production of the Stag to meet the purchase requirements of AWS and whether those units will result in future sales opportunities to federal and state entities. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. The Company has attempted to identify forward-looking statements by terminology including ”believes,” ”estimates,” ”anticipates,” ”expects,” ”plans,” ”projects,” ”intends,” ”potential,” ”may,” ”could,” ”might,” ”will,” ”should,” ”approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors. Any forward-looking statements contained in this release speak only as of its date. The Company undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K and subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K filed with the SEC, which are available on the SEC’s website, www.sec.gov.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d4a1b298-751e-4a84-8a13-aa02fb3fec6e

NEW YORK, July 05, 2023 (GLOBE NEWSWIRE) — Cipher Mining Inc. (NASDAQ:CIFR) (“Cipher” or the “Company”) today released its unaudited production and operations update for June 2023.

Key Highlights

Key Metrics	June 2023*
BTC Mined	360
Power Sales Equivalent BTC 1	41
BTC Sold	350
BTC Held	417
Deployed Mining Rigs	65,000
Month End Operating Hash Rate (EH/s)	6.7

*Approximate values

Management Commentary

In June, Cipher continued to expand operations at its Odessa facility and finished June with the potential to mine up to 17.1 bitcoin² per day.

“The month of June featured challenging operating conditions. Texas experienced record high temperatures, weak wind production and record demand for power as we entered the critical 4CP summer months,” said Tyler Page, CEO of Cipher. “Against this backdrop, we are delighted to announce production numbers that reflect not only our ability to navigate tough operating conditions and manage our mining fleet during extreme temperatures, but also our optimization of production through power sales. In this month’s report, we introduced a Power Sales Equivalent BTC line item that is not included in our BTC Mined statistic and is an estimate of our incremental power sales for the month expressed in bitcoin terms. We hope this provides insight into our monthly revenue potential beyond just our bitcoin production. With the extreme demand for power in June, we also saw our Odessa PPA counterparty use a significant amount of their annual curtailment budget, which demonstrates the value of bitcoin mining as an industry in supporting the grid at its most vulnerable times and positions us well for the remainder of 2023 if market power prices remain high.”

“As we continue to expand our mining capacity, we aim to deliver operational excellence, even in the hot Texas summer. Our team focuses on efficient optimization of the portfolio, whether that is through the mix of rigs in use, underclocking our machines, or selling power back to the grid at the most valuable times. We are also pleased to announce that we have taken delivery of all 11,000 Canaan rigs that we recently purchased. And with the final build out of the infrastructure in the next few months, we are well on track to deliver on our goal of 7.2 EH/s by the end of Q3.”

Satellite Image of the Odessa Data Center

Final Shipment of Canaan Rigs

Bitcoin Production and Operations Updates for June 2023
Cipher received the delivery of all 11,000 Canaan rigs recently purchased and incrementally began to energize the new rigs during the month of June, bringing Cipher’s total deployed rig count to approximately 65,000. Cipher produced ~360 BTC in June, representing a ~27% decrease in production relative to the previous month. As part of its regular treasury management process, Cipher sold ~350 BTC in June and executed its first bitcoin futures and options trades, ending the month with a balance of ~417 BTC.

About Cipher

Cipher is an emerging technology company focused on the development and operation of bitcoin mining data centers. Cipher is dedicated to expanding and strengthening the Bitcoin network’s critical infrastructure. Together with its diversely talented team and strategic partnerships, Cipher aims to be a market leader in bitcoin mining growth and innovation. To learn more about Cipher, please visit https://www.ciphermining.com/

Forward Looking Statements

This press release contains certain forward-looking statements within the meaning of the federal securities laws of the United States. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and includes this statement for purposes of complying with these safe harbor provisions. Any statements made in this press release that are not statements of historical fact, including statements about our beliefs and expectations regarding our future results of operations and financial position, business strategy, timing and likelihood of success, potential expansion of bitcoin mining data centers, and management plans and objectives, are forward-looking statements and should be evaluated as such. Forward-looking statements include information concerning possible or assumed future results of operations, including descriptions of our business plan and strategies. These forward-looking statements generally are identified by the words “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “seeks,” “intends,” “targets,” “projects,” “contemplates,” “believes,” “estimates,” “strategy,” “future,” “forecasts,” “opportunity,” “predicts,” “potential,” “would,” “will likely result,” “continue,” and similar expressions (including the negative versions of such words or expressions).

These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Cipher and our management, are inherently uncertain. Such forward-looking statements are subject to risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied by such forward looking statements. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: volatility in the price of Cipher’s securities due to a variety of factors, including changes in the competitive and regulated industry in which Cipher operates, variations in performance across competitors, changes in laws and regulations affecting Cipher’s business, and the ability to implement business plans, forecasts, and other expectations and to identify and realize additional opportunities. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of our Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 14, 2023, and in Cipher’s subsequent filings with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Cipher assumes no obligation and, except as required by law, does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.

Contacts:

Investor Contact:

Josh Kane
Head of Investor Relations at Cipher Mining
[email protected]

Media Contact:

Ryan Dicovitsky / Kendal Till
Dukas Linden Public Relations
[email protected]

Photos accompanying this announcement are available at :

https://www.globenewswire.com/NewsRoom/AttachmentNg/f59e7611-1e4c-43d1-8b96-11a5aefeb9c2

https://www.globenewswire.com/NewsRoom/AttachmentNg/eefe09d1-48c7-4ddf-82bf-1592c3868643

______________________

¹
Represents unaudited power sales estimates for the month of June (based on current meter data and nodal prices) divided by the bitcoin price as of June 30, 2023 of ~$30,449
² Assumes network hash rate of 370 EH/s and 946 bitcoins mined per day 

• Simufilam Slowed Cognitive Decline by 38% Versus Placebo Over 6 months in Patients with Mild-to-Moderate Alzheimer’s Disease.
• Drug Effects Favored Mild Alzheimer’s Disease.
• In Mild Alzheimer’s, Simufilam Improved Cognition Scores Over 6 Months.
• In Mild Alzheimer’s, Simufilam Stabilized Cognition Scores Over 18 Months.
• Oral Simufilam Continues to be Safe, Well Tolerated.
  

AUSTIN, Texas, July 05, 2023 (GLOBE NEWSWIRE) — Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company, today announced top-line clinical results from its Cognition Maintenance Study (CMS). The CMS is a small proof-of-concept study designed to demonstrate the effects of drug versus placebo in a randomized withdrawal trial design. The study enrolled 157 patients with mild-to-moderate Alzheimer’s disease, a more advanced and difficult-to-treat stage of disease.

In this double-blind, placebo-controlled, randomized study, all patients first received open-label simufilam 100 mg for 12 months; patients were then randomized (1:1) to receive either simufilam 100 mg or placebo for 6 months. 16 U.S. clinical sites participated. The CMS had one pre-specified cognitive endpoint: mean change in ADAS-Cog11 scores over 6 months, drug versus placebo.

Simufilam treatment for 6 months slowed cognitive decline by 38% compared to placebo in mild-to-moderate Alzheimer’s disease (MMSE 16-26). The placebo arm declined 1.5 points on ADAS-Cog, and this arm declined at all measured timepoints. The simufilam arm declined 0.9 points on ADAS-Cog, a 38% difference in favor of drug at month 6 (95% CI, – 2.1 to 1.0; not significant for sample sizes). See Table 1 and Chart 1.

Table 1: Results of Randomized Withdrawal Study – cognitive change, full analysis set (FAS)

Full Analysis Set	Simufilam 100 mg (N = 78)	Placebo (N = 77)	Numerical Difference	Percent Difference
6-month Change in ADAS-Cog	0.9 point Decline	1.5 point Decline	– 0.6	38% in favor of drug

Upon randomization into the CMS, mean baseline MMSE scores were 18.6 and 18.1 for the simufilam and placebo arms, respectively. Mean baseline ADAS-Cog scores were 19.3 and 21.9 for the simufilam and placebo arms, respectively.

“Monoclonal antibody drugs have slowed cognitive decline by 35% or less in early Alzheimer’s patients in large Phase 3 trials over 18 months,” said James Kupiec, MD, Chief Medical Officer. “In this context, we believe results of our 6-month study are encouraging, despite vast differences in patient selection and the design and results of our randomized withdrawal study compared to large Phase 3 trials.”

Simufilam Drug Effects Favored Patients with Mild Alzheimer’s Disease.

Simufilam treatment for 6 months slowed cognitive decline > 200% compared to placebo in

mild

Alzheimer’s disease. CMS patients with mild Alzheimer’s (MMSE 21-26) on placebo declined 0.6 points on ADAS-Cog over 6 months as a group. CMS patients with mild Alzheimer’s on simufilam improved 0.6 points over 6 months as a group, a 205% difference in favor of drug (95% CI, – 2.6 to 0.4; not significant for sample sizes). See Table 2 and Chart 2.

Table 2: Results of Randomized Withdrawal Study – cognitive change, mild patients

Mild Patients	Simufilam 100 mg (N= 40)	Placebo (N= 36)	Numerical Difference	Percent Difference
6-month Change in ADAS-Cog	0.6 point Improvement	0.6 point Decline	– 1.1	205% in favor of drug

“Patients started out taking open-label simufilam for 12 months prior to enrolling in the CMS,” said Remi Barbier, President & CEO. “CMS patients on placebo were, in effect, withdrawn from simufilam for 6 months. This placebo arm declined while the CMS arm randomized to simufilam improved. We believe the emerging separation of cognitive scores between these two arms represents a drug effect.”

Suzanne Hendrix, PhD, CEO of Pentara Corporation, added: “Results for simufilam continue to be noteworthy. The lack of disease progression in cognition, as measured by the ADAS-Cog over 18 months of treatment in mild patients, is well outside the range in historic placebo decline rates from numerous other studies. The placebo group in the CMS has started to decline again but continues to maintain benefit over historical placebo groups.”

Upon randomization into the CMS, mean baseline MMSE scores for mild patients were MMSE 24.0 and MMSE 24.1 for the simufilam and placebo arms, respectively. Mean baseline ADAS-Cog scores for mild patients were 11.0 and 11.2 for the simufilam and placebo arms, respectively.

Simufilam for 18 months stabilized cognition in

mild

Alzheimer’s disease.

After taking open-label simufilam for 12 months, 76 patients with mild Alzheimer’s disease (MMSE 21-26) enrolled in the CMS and were randomized to receive either simufilam (N=40) or placebo (N=36) for 6 months. Mild patients randomized to simufilam in the CMS showed no material decline in ADAS-Cog scores over 18 months as a group, indicating stable cognition. Mild patients randomized to placebo in the CMS (and therefore withdrawn from simufilam treatment for 6 months) declined by 0.8 points in ADAS-Cog as a group. See Figure 1.

Figure 1. Historical declines on ADAS-Cog over 18 months in Alzheimer’s disease (MMSE 20-30), placebo arms vs simufilam treatment.



¹


Notes: results shown for CLARITY P3 trial of lecanemab; EMERGE and ENGAGE P3 studies of aducanumab; and TRAILBLAZER P3 trial of donanemab; in this figure, the CMS is referred to as the ‘PTI-125-04’ study; ‘Simufilam100mg-Simufilam100mg’ refers to patients who received simufilam in both the open-label phase and the CMS; ‘Simufilam100mg-Placebo’ refers to patients who received simufilam in the open-label phase and placebo in the CMS.

Safety Data

Simufilam 100 mg twice daily was safe and well tolerated in this study. There were no drug-related serious adverse events. No treatment-emergent adverse events (TEAEs) occurred in 5% or more of study participants in the CMS.

Discussion

The CMS was a randomized withdrawal study. Patients who completed 12 months of open-label simufilam treatment were all invited to participate in the CMS. It is not known how long a washout period may be needed to remove lingering drug effects, if any, from prior treatment with open-label simufilam for 12 months.

In this small study of oral simufilam in patients with mild-to-moderate Alzheimer’s disease, the pre-specified cognitive endpoint showed a 38% decline in ADAS-Cog over six months in favor of simufilam, with good drug safety. Effects were pronounced in mild patients. Mean baseline MMSE and ADAS-Cog scores were approximately balanced given the small size of each arm.

Analysis of Efficacy Endpoints

The pre-specified cognition endpoints were analyzed by Pentara Corporation, an independent consulting firm that specializes in complex statistical analysis of clinical trial results. Suzanne Hendrix, PhD, CEO of Pentara, has over 150 peer-reviewed publications of clinical trial results and statistical approaches for clinical trials, many focusing on statistical methodology for Alzheimer’s disease.

Chain of Custody for Clinical Data

Investigator sites collected clinical data from study participants. Sites entered their clinical data directly into an electronic data capture system managed by an independent, outside data management vendor. The data management vendor also maintains the clinical database. The data management vendor transmitted the clinical database directly to Pentara Corporation for analysis.

Study Limitations

The CMS is a proof-of-concept study involving a small number of patients and limited data. Top-line clinical CMS results do not constitute, and should not be interpreted as, regulatory evidence of safety or efficacy for simufilam in Alzheimer’s disease. Rigorous evidence for drug safety and efficacy is derived from one or more large, randomized placebo-controlled Phase 3 studies. The limited size of the CMS may introduce clinical or statistical bias or may generate results that may not fully distinguish between drug effects and random variation. Different methods of statistical analysis on clinical data from the same study may lead to objectively different numerical results. These and other statistical and clinical features of our CMS study add complexity or limitations to the scope of data interpretation. In addition, ‘Top-line data’ is a summary of the clinical data prior to the completion of a full and final audit or quality-control of the clinical database. We are communicating top-line data so that stakeholders may have timely access to a summary of the CMS findings prior to us receiving the final dataset. Final data may change from today’s top-line data.

On-going Phase 3 Studies with Simufilam

Cassava Sciences is currently evaluating simufilam tablets for Alzheimer’s disease dementia in two Phase 3 clinical studies. These are large, randomized, double-blind, placebo-controlled trials. The Phase 3 program is recruiting a total of approximately 1,750 patients with mild-to-moderate Alzheimer’s disease who also meet other study eligibility criteria. Both Phase 3 studies have received a Special Protocol Assessment (SPA) from the U.S. Food and Drug Administration. The Phase 3 studies are actively recruiting Alzheimer’s patients in over 100 clinical sites in the United States, Canada, Puerto Rico, South Korea and Australia.

Patient enrollment is expected to be completed for both Phase 3 studies by yearend 2023.

About Simufilam

Simufilam is Cassava Sciences’ proprietary, small molecule (oral) drug candidate that restores the normal shape and function of altered filamin A (FLNA) protein in the brain. Cassava Sciences owns worldwide development and commercial rights to its research programs in Alzheimer’s disease, and related technologies, without royalty obligations to any third party.

About Cassava Sciences, Inc.

Cassava Sciences is a clinical-stage biotechnology company based in Austin, Texas. Our mission is to detect and treat neurodegenerative diseases, such as Alzheimer’s disease. Our novel science is based on stabilizing—but not removing—a critical protein in the brain. Our product candidates have not been approved by any regulatory authority, and their safety, efficacy or other desirable attributes have not been established.

For more information, please visit: https://www.CassavaSciences.com

For More Information Contact:

Eric Schoen, Chief Financial Officer
(512) 501-2450
[email protected]

Cautionary Note Regarding Forward-Looking Statements:


This news release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, relating to:
the design, scope, conduct or intended purpose of our randomized withdrawal study or Phase 3 program of simufilam in patients with Alzheimer’s disease; the ability of simufilam to provide patients with drug effects; the apparent ability of simufilam to favor patients with mild Alzheimer’s disease;
the safety or tolerance of simufilam in the CMS clinical trial; our current expectations regarding timing of and the target patient enrollment numbers for our Phase 3 studies;
any expected clinical results of Phase 3 studies; the treatment of people with Alzheimer’s disease dementia; the safety or efficacy of simufilam in people with Alzheimer’s disease dementia;
comments made by our employees regarding simufilam, drug effect, and the treatment of Alzheimer’s disease; and potential benefits, if any, of our product candidates. These statements may be identified by words such as “may,” “anticipate,” “believe,” “could,” “expect,” “would”, “forecast,” “intend,” “plan,” “possible,” “potential,” and other words and terms of similar meaning.

Simufilam is our investigational product candidate. It is not approved by any regulatory authority in any jurisdiction and its safety, efficacy or other desirable attributes have not been established in patients.

Drug development involves a high degree of risk, and only a small number of research and development programs result in regulatory approval and commercialization of a product.
Clinical results from our prior studies may not be indicative of results of future or larger scale clinical trials and do not ensure regulatory approval.
You should not place undue reliance on these statements or any scientific data we present or publish.

Such statements are based largely on our current expectations and projections about future events. Such statements speak only as of the date of this news release and are subject to a number of risks, uncertainties and assumptions, including, but not limited to, those risks relating to the ability to conduct or complete clinical studies on expected timelines, to demonstrate the specificity, safety, efficacy or potential health benefits of our product candidates, any unanticipated impacts of inflation on our business operations, and including those described in the section entitled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2022, and future reports to be filed with the SEC. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from expectations in any forward-looking statement. In light of these risks, uncertainties and assumptions, the forward-looking statements and events discussed in this news release are inherently uncertain and may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Accordingly, you should not rely upon forward-looking statements as predictions of future events. Except as required by law, we disclaim any intention or responsibility for updating or revising any forward-looking statements contained in this news release. For further information regarding these and other risks related to our business, investors should consult our filings with the SEC, which are available on the SEC’s website at


www.sec.gov


.

This news release may also contain statistical data and drug information based on independent industry publications or other publicly available information. We have not independently verified the accuracy or completeness of the data contained in these publicly available sources of data and information. Accordingly, we make no representations as to the accuracy or completeness of such data or information. You are cautioned not to give undue weight to such data.

The content of this presentation is solely our responsibility and does not represent the official views of the National Institutes of Health or any other government agency.

___________________________________

¹ Figure 1: Forest plot by Pentara Corporation. Data was sourced from the placebo groups in randomized, controlled trials of monoclonal antibodies conducted by other sponsors in Alzheimer’s disease (MMSE 20-30).

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/c920d107-3c33-450a-b801-48b008614378

https://www.globenewswire.com/NewsRoom/AttachmentNg/35197b1c-ad89-4067-b692-2163afc22158

https://www.globenewswire.com/NewsRoom/AttachmentNg/bb23047a-5f15-4047-b402-c3cce6d70290

NEW YORK, July 05, 2023 (GLOBE NEWSWIRE) — Nasdaq, Inc. (Nasdaq: NDAQ) today announced the election of all nominated directors to the boards of the U.S. exchanges operated by the company, which include The Nasdaq Stock Market LLC, Nasdaq PHLX LLC, Nasdaq BX, Inc., Nasdaq ISE, LLC, Nasdaq MRX, LLC, and Nasdaq GEMX, LLC:

• Kathlyn Card Beckles, Chief Legal Officer, Verisk Analytics, Inc.
• Tal Cohen, President of Market Platforms, Nasdaq, Inc.
• Michael J. Curran, Retired Chairman and CEO, Boston Stock Exchange
• Anne Marie Darling, Partner, Global Banking and Markets Division, Goldman Sachs
• David J. Frear, Former CFO, SiriusXM Holdings Inc.
• Thomas A. Kloet, Retired CEO and Executive Director, TMX Group Limited
• Anita Lynch, Former Chief Data Officer, New Relic, Inc.
• David Rosato, Senior EVP and CFO, Berkshire Bank & Berkshire Hills Bancorp
• Andrew J. Schultz, Head of Strategic Options Business, The Susquehanna International Group of Companies
• Elizabeth Wideman, SVP and Senior Deputy General Counsel, Comcast Corporation

For further governance information, visit: http://ir.nasdaq.com/corporate-governance/nasdaq-stock-market/board-of-directors.

About Nasdaq

Nasdaq (Nasdaq: NDAQ) is a leading global technology company serving corporate clients, investment managers, banks, brokers, and exchange operators as they navigate and interact with the global capital markets and the broader financial system. We aspire to deliver world-leading platforms that improve the liquidity, transparency, and integrity of the global economy. Our diverse offering of data, analytics, software, exchange capabilities, and client-centric services enables clients to optimize and execute their business vision with confidence. To learn more about the company, technology solutions, and career opportunities, visit us on LinkedIn, on Twitter @Nasdaq, or at www.nasdaq.com.

Nasdaq Media Contact:

Nick Eghtessad
+1.929.996.8894
[email protected]

Nasdaq Investor Relations Contact

Ato Garrett
+1.212.401.8737
[email protected]

-NDAQF- 

SUNNYVALE, Calif., July 05, 2023 (GLOBE NEWSWIRE) —

News Summary

Fortinet® (NASDAQ: FTNT), the global cybersecurity leader driving the convergence of networking and security, announced that it will hold a conference call to discuss its second quarter 2023 financial results on Thursday, August 3, at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).

Fortinet’s financial results conference call will be broadcast live in listen-only mode on the company’s investor relations website at http://investor.fortinet.com. While not required, it is recommended that you join at least 10 minutes prior to the event start.

The CEO and CFO’s prepared remarks, supplemental slides and a call replay will be accessible from the Quarterly Earnings page on the Investor Relations page of Fortinet’s website at https://investor.fortinet.com/quarterly-earnings.

About Fortinet


Fortinet
 (NASDAQ: FTNT) is a driving force in the evolution of cybersecurity and the convergence of networking and security. Our mission is to secure people, devices, and data everywhere, and today we deliver cybersecurity everywhere you need it with the largest integrated portfolio of over 50 enterprise-grade products. Well over half a million customers trust Fortinet’s solutions, which are among the most deployed, most patented, and most validated in the industry. The Fortinet Training Institute, one of the largest and broadest training programs in the industry, is dedicated to making cybersecurity training and new career opportunities available to everyone. FortiGuard Labs, Fortinet’s elite threat intelligence and research organization, develops and utilizes leading-edge machine learning and AI technologies to provide customers with timely and consistently top-rated protection and actionable threat intelligence. Learn more at https://www.fortinet.com, the Fortinet Blog, and FortiGuard Labs.

FTNT-F

Copyright © 2023 Fortinet, Inc. All rights reserved. The symbols ® and ™ denote respectively federally registered trademarks and common law trademarks of Fortinet, Inc., its subsidiaries and affiliates. Fortinet’s trademarks include, but are not limited to, the following: Fortinet, the Fortinet logo, FortiGate, FortiOS, FortiGuard, FortiCare, FortiAnalyzer, FortiManager, FortiASIC, FortiClient, FortiCloud, FortiCore, FortiMail, FortiSandbox, FortiADC, FortiAI, FortiAP, FortiAppEngine, FortiAppMonitor, FortiAuthenticator, FortiBalancer, FortiBIOS, FortiBridge, FortiCache, FortiCall, FortiCam, FortiCamera, FortiCarrier, FortiCASB, FortiCenter, FortiCentral, FortiConnect, FortiController, FortiConverter, FortiCWP, FortiDB, FortiDDoS, FortiDeceptor, FortiDirector, FortiDNS, FortiEDR, FortiExplorer, FortiExtender, FortiFirewall, FortiFone, FortiGSLB, FortiHypervisor, FortiInsight, FortiIsolator, FortiLocator, FortiLog, FortiMeter, FortiMoM, FortiMonitor, FortiNAC, FortiPartner, FortiPenTest, FortiPhish, FortiPortal, FortiPresence , FortiProtect, FortiProxy, FortiRecorder, FortiReporter, FortiSASE, FortiScan, FortiSDNConnector, FortiSIEM, FortiSDWAN, FortiSMS, FortiSOAR, FortiSwitch, FortiTester, FortiToken, FortiTrust, FortiVoice, FortiVoIP, FortiWAN, FortiWeb, FortiWiFi, FortiWLC, FortiWLCOS and FortiWLM.

Other trademarks belong to their respective owners. Fortinet has not independently verified statements or certifications herein attributed to third parties and Fortinet does not independently endorse such statements. Notwithstanding anything to the contrary herein, nothing herein constitutes a warranty, guarantee, contract, binding specification or other binding commitment by Fortinet or any indication of intent related to a binding commitment, and performance and other specification information herein may be unique to certain environments. This news release may contain forward-looking statements that involve uncertainties and assumptions, such as statements regarding technology releases among others. Changes of circumstances, product release delays, or other risks as stated in our filings with the Securities and Exchange Commission, located at www.sec.gov, may cause results to differ materially from those expressed or implied in this press release. If the uncertainties materialize or the assumptions prove incorrect, results may differ materially from those expressed or implied by such forward-looking statements and assumptions. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Fortinet assumes no obligation to update any forward-looking statements, and expressly disclaims any obligation to update these forward-looking statements.

Media Contact:	Investor Contact:	Analyst Contact:
Tiffany Curci	Peter Salkowski	Brian Greenberg
Fortinet, Inc.	Fortinet, Inc.	Fortinet, Inc.
208-880-8134	408-331-4595	408-235-7700
[email protected]	[email protected]	[email protected]

 

FORT WAYNE, Ind., July 05, 2023 (GLOBE NEWSWIRE) — Franklin Electric Co., Inc. (NASDAQ: FELE) announced today that Donald Kenney, Vice President and President, Global Water, will be retiring after 25 years with the company. Kenney was a driving force behind Franklin Electric’s Global Water growth and strategy over the last decade, and he will remain with the company through the end of July to ensure a smooth transition to his successor, Greg Levine. Levine will join Franklin Electric on July 3 from Nidec Corporation, where he served as President of the Motion Control and Drives business for the past six years. In his new role, Levine will be responsible for Franklin Electric’s global Water Systems business.

“Don’s strategic vision and customer-centric approach was essential to our growth these past few years,” said Gregg Sengstack, Chairperson and Chief Executive Officer. “We are excited to bring on a leader with a proven track record of identifying and nurturing growth opportunities. This insight will allow us to build on the strong foundation we have in place.”

Levine served in global profit and loss and technology roles for Nidec for 13 years, where he oversaw an international team of 3,800 individuals across 13 operational sites. During his time with Nidec, Levine positioned the company to grow two-fold in five years through organic growth and acquisitions. Before working at Nidec, Levine held senior engineering roles at Emerson for 15 years. “Greg’s disciplined technology focus and industry insight will help him guide Franklin Electric well into the future as we explore new products, markets and customers,” said Mr. Sengstack.

About Franklin Electric


Franklin Electric is a global leader in the production and marketing of systems and components for the movement of water and energy. Recognized as a technical leader in its products and services, Franklin Electric serves customers around the world in residential, commercial, agricultural, industrial, municipal, and fueling applications. Franklin Electric is proud to be named in Newsweek’s lists of America’s Most Responsible Companies and Most Trustworthy Companies for 2023 and America’s Climate Leaders 2023 by USA Today.

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein, including those relating to market conditions or the Company’s financial results, costs, expenses or expense reductions, profit margins, inventory levels, foreign currency translation rates, liquidity expectations, business goals and sales growth, involve risks and uncertainties, including but not limited to, risks and uncertainties with respect to general economic and currency conditions, various conditions specific to the Company’s business and industry, weather conditions, new housing starts, market demand, competitive factors, changes in distribution channels, supply constraints, effect of price increases, raw material costs, technology factors, integration of acquisitions, litigation, government and regulatory actions, the Company’s accounting policies, future trends, epidemics and pandemics, and other risks which are detailed in the Company’s Securities and Exchange Commission filings, included in Item 1A of Part I of the Company’s Annual Report on Form 10-K for the fiscal year ending December 31, 2022, Exhibit 99.1 attached thereto and in Item 1A of Part II of the Company’s Quarterly Reports on Form 10-Q. These risks and uncertainties may cause actual results to differ materially from those indicated by the forward-looking statements. All forward-looking statements made herein are based on information currently available, and the Company assumes no obligation to update any forward-looking statements.

Contact:	Jeff Taylor
	Franklin Electric Co., Inc.
	260.824.2900

This eagerly awaited event will serve as a unique platform for the gathering of renowned experts in cutting-edge technologies such as .NET MAUI, Blazor, React and Angular that are shaping the future of digital experiences

BURLINGTON, Mass., July 05, 2023 (GLOBE NEWSWIRE) — Progress (Nasdaq: PRGS), the trusted provider of application development and infrastructure software, today announced that this year’s edition of DevReach, its premier developer conference, will take place on October 25-26, 2023, at the Sofia Event Center in Sofia, Bulgaria. Registration is now open.

For the 13^th edition of DevReach, Progress brings together 25 world-renowned industry speakers from companies such as Cisco, Microsoft, Progress and VMware, among others, to share best practices and discuss the latest in the application development space. These industry visionaries will provide their insights to empower developers to take their skills to new heights and drive next-level digital experiences.

Developers are front and center when it comes to building applications that are effective in delivering successful digital experiences. DevReach 2023 provides hands-on exploration of software languages and the latest frameworks in an effort to reduce the friction developers face, freeing time to focus on solving the most complex challenges and deliver meaningful business results for their organizations.

True to its community spirit, DevReach will provide a space for developers to reconnect, collaborate and learn over two days of sessions on .NET, JavaScript, AI, design and more. In addition to the value-packed agenda, attendees will enjoy a unique event experience through a special 360-degree projection of the stage, allowing them to fully immerse themselves in the sessions.

“DevReach is a powerful and impactful event that features top teachers, trainers and presenters from around the world, delivering topics that are relevant and empower developers with the knowledge to engage with the latest technologies and tools,” said Jeremy Likness, Principal Product Manager, Microsoft. “It’s a conference that brings together thought leaders and community members with a unique platform to network and learn.”

DevReach 2023 keynote speakers will be Scott Hunter, VP Director of Program Management for Azure, Microsoft, and Richard Campbell, host of .NET Rocks & RunAs Radio. In his session, Hunter will delve into the potential of AI in reshaping the landscape of cloud technologies. Campbell will close the first conference day with predictions on how software development is set to evolve and how what’s trending will impact software developers.

The DevReach 2023 lineup consists of 25 tech industry leaders and experts, including:

• Layla Porter, Developer Advocate, VMware
• David Ortinau, Principal Product Manager, Microsoft
• Gerald Versluis, Senior Software Engineer, Microsoft
• Jennifer Wadella, Director of Angular Development, Bitovi
• Josh Goldberg, Open Source Developer
• Yosef Arbiv, R&D Group Leader, Cisco
• Peter Vogel, System Architect & Principal, PH&V Information Services
• Gift Egwuenu, Developer Advocate, Cloudflare
• Alyssa Nicoll, Senior Developer Advocate, Progress
• Kathryn Grayson Nanz, Developer Advocate, Progress
• Sam Basu, Principal Developer Advocate, Progress
• Ed Charbeneau, Principal Developer Advocate, Progress

In addition, Progress will host an on-site livestream studio where Jeff Fritz, Principal Program Manager, Microsoft, will be writing code live and speaking exclusively with the events’ speakers. Attendees can join the studio audience or tune in on the CodeItLive Twitch channel.

“Our mission is to empower developers to build high-quality apps, meeting even the stringent requirements, with ease and speed,” said Sara Faatz, Director, Technology Community Relations, Progress. “We know well from our own experience that the international developer community likes to gather together to collaborate and learn, and we are excited that DevReach 2023 will again offer that opportunity. We believe that attendees will leave the event with new connections and insightful takeaways that will help them become even better developers.”

For more information about DevReach and to register for the conference, visit www.telerik.com/devreach.

About Progress

Dedicated to propelling business forward in a technology-driven world, Progress (Nasdaq: PRGS) helps businesses drive faster cycles of innovation, fuel momentum and accelerate their path to success. As the trusted provider of the best products to develop, deploy and manage high-impact applications, Progress enables customers to develop the applications and experiences they need, deploy where and how they want and manage it all safely and securely. Hundreds of thousands of enterprises, including 1,700 software companies and 3.5 million developers, depend on Progress to achieve their goals—with confidence. Learn more at www.progress.com, and follow us on LinkedIn, YouTube, Twitter, Facebook and Instagram.

Progress and DevReach are trademarks or registered trademarks of Progress Software Corporation and/or its subsidiaries or affiliates in the U.S. and other countries. Any other names contained herein may be trademarks of their respective owners.

Press Contact:

Kim Baker
Progress
+1-800-213-3407
[email protected]

PALO ALTO, Calif., July 05, 2023 (GLOBE NEWSWIRE) — Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announces record revenue for the month of June 2023 and is providing certain preliminary unaudited financial results for the month ended June 30, 2023, quarter ended June 30, 2023, and year-to-date as of June 30, 2023, based on currently available information.

The Company estimates that:

• ZTlido gross sales for (i) June 2023 were in the range of $13.5 million to $14.5 million, compared to $7.4 million in June 2022, representing growth in the range of 82% to 96%; (ii) the quarter ended June 2023 were in the range of $37.5 million to $39.0 million, compared to $21.0 million for the quarter ended June 2022, representing growth in the range of 79% to 86%; and (iii) year-to-date June 2023 were in the range of $64.2 million to $67.3 million, compared to $39.4 million for year-to-date June 2022, representing growth in the range of 63% to 71%. Scilex is well positioned to continue its growth over the next several years.
• ZTlido net sales for (i) June 2023 were in the range of $4.0 million to $5.1 million, compared to $3.3 million in June 2022, representing growth in the range of 21% to 54%; (ii) the quarter ended June 2023 were in the range of $11.2 million to $13.6 million, compared to $7.9 million for the quarter ended June 2022, representing growth in the range of 42% to 72%; and (iii) year-to-date June 2023 were in the range of $20.5 million to $23.0 million, compared to $14.7 million for year-to-date June 2022, representing growth in the range of 39% to 56%.
• Total product gross sales for (i) June 2023 were in the range of $14.0 million to $15.0 million, compared to $7.4 million in June 2022, representing growth in the range of 89% to 103%; (ii) the quarter ended June 2023 were in the range of $39.0 million to $40.0 million, compared to $21.0 million for the quarter ended June 2022, representing growth in the range of 86% to 90%; and (iii) year-to-date June 2023 were in the range of $65.6 million to $69.0 million, compared to $39.4 million for year-to-date June 2022, representing growth in the range of 66% to 75%. Scilex believes the year-to-date gross sales will reflect in the range of $140 million to $150 million annualized run rate.
• Total product net sales for (i) June 2023 were in the range of $4.2 million to $5.2 million, compared to $3.3 million in June 2022, representing growth in the range of 27% to 57%; (ii) the quarter ended June 2023 were in the range of $12.0 million to $14.0 million, compared to $7.9 million for the quarter ended June 2022, representing growth in the range of 52% to 77%; and (iii) year-to-date June 2023 were in the range of $20.8 million to $24.0 million, compared to $14.7 million for year-to-date June 2022, representing growth in the range of 41% to 63%.

This preliminary financial data has been prepared by and is the responsibility of Scilex. Scilex has not fully completed its review of these preliminary financial results for the one month ended June 30, 2023, quarter ended June 30, 2023, and year-to-date as of June 30, 2023. Scilex’s independent auditor has not reviewed or audited these preliminary estimated financial results. Scilex’s actual results may differ materially from these preliminary financial results, and may be outside the estimated ranges.

About Scilex Holding Company

Scilex Holding Company is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Scilex is uncompromising in its focus to become the global pain management leader committed to social, environmental, economic, and ethical principles to responsibly develop pharmaceutical products to maximize quality of life. Results from the Phase III Pivotal Trial C.L.E.A.R. Program for SEMDEXA^TM, its novel, non-opioid product for the treatment of lumbosacral radicular pain (sciatica), were announced in March 2022. Scilex submitted a request to the FDA for a type C meeting for purposes of pre-NDA discussion with the FDA. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with moderate to severe pain. Scilex launched its first commercial product ZTlido® in October 2018, in-licensed a commercial product Gloperba® in June 2022, and launched its third FDA-approved product Elyxyb^TM in April 2023. It is also developing its late-stage pipeline, which includes a pivotal Phase 3 candidate, and one Phase 2 and one Phase 1 candidate. Its commercial product, ZTlido® (lidocaine topical system) 1.8%, or ZTlido®, is a prescription lidocaine topical product approved by the U.S. Food and Drug Administration for the relief of pain associated with post-herpetic neuralgia, which is a form of post-shingles nerve pain. Scilex in-licensed the exclusive right to commercialize Gloperba® (colchicine USP) oral solution, an FDA-approved prophylactic treatment for painful gout flares in adults, in the U.S. Scilex in-licensed the exclusive rights to commercialize Elyxyb^TM (celecoxib oral solution) in the U.S. and Canada, the only FDA-approved ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults. Scilex launched Elyxyb^TM in April 2023 and is planning to commercialize Gloperba® in the fourth quarter of 2023 and is well-positioned to market and distribute those products. Scilex’s three product candidates are SP-102 (injectable dexamethasone sodium phosphate viscous gel product containing 10 mg dexamethasone), or SEMDEXA™, a Phase 3, novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, with FDA Fast Track status; SP-103 (lidocaine topical system) 5.4%, a Phase 2 study, triple-strength formulation of ZTlido®, for the treatment of acute low back pain, with FDA Fast Track status; and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule, for the treatment of chronic pain, fibromyalgia that has completed multiple Phase 1 trial programs and is expected to initiate Phase 2 trials in 2023. For further information regarding the SP-102 Phase 3 efficacy trial, see NCT identifier NCT03372161 – Corticosteroid Lumbar Epidural Analgesia for Radiculopathy – Full Text View – ClinicalTrials.gov.

Scilex Holding Company is headquartered in Palo Alto, California.

Forward-Looking Statements

This press release and any statements made for and during any presentation or meeting concerning the matters discussed in this press release contain forward-looking statements related to Scilex and its subsidiaries under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding Scilex’s preliminary unaudited financial results for the one month ended June 30, 2023, quarter ended June 30, 2023, and year-to-date as of June 30, 2023, Scilex’s plans to commercialize Gloperba® in the fourth quarter of 2023, Scilex’s belief that it is well positioned to continue its growth over the next several years, Scilex’s long-term objectives and commercialization plans, Scilex’s potential to attract new capital, future opportunities for Scilex, Scilex’s future business strategies, the expected cash resources of Scilex and the expected uses thereof; Scilex’s current and prospective product candidates, planned clinical trials and preclinical activities and potential product approvals, as well as the potential for market acceptance of any approved products and the related market opportunity; statements regarding ZTlido®, Gloperba®, ELYXYB^TM, SP-102 (SEMDEXA™), SP-103 or SP-104, if approved by the FDA; Scilex’s development and commercialization plans; and Scilex’s products, technologies and prospects.

Risks and uncertainties that could cause Scilex’s actual results to differ materially and adversely from those expressed in our forward-looking statements, include, but are not limited to: the risk that Scilex’s actual unaudited financial results for the one month ended June 30, 2023, quarter ended June 30, 2023 and year-to-date as of June, 2023 may differ from those set forth in this press release; risks associated with the unpredictability of trading markets and whether a market will be established for Scilex’s common stock; general economic, political and business conditions; risks related to the ongoing COVID-19 pandemic; the risk that the potential product candidates that Scilex develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; risks relating to uncertainty regarding the regulatory pathway for Scilex’s product candidates; the risk that Scilex will be unable to successfully market or gain market acceptance of its product candidates; the risk that Scilex’s product candidates may not be beneficial to patients or successfully commercialized; the risk that Scilex has overestimated the size of the target patient population, their willingness to try new therapies and the willingness of physicians to prescribe these therapies; risks that the results of the Phase 2 trial for SP-103 or Phase 1 trials for SP-104 may not be successful; risks that the prior results of the clinical trials of SP-102 (SEMDEXA™), SP-103 or SP-104 may not be replicated; regulatory and intellectual property risks; and other risks and uncertainties indicated from time to time and other risks set forth in Scilex’s filings with the Securities and Exchange Commission. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and Scilex undertakes no obligation to update any forward-looking statement in this press release except as may be required by law.

Contacts:

Investors and Media
Scilex Holding Company
960 San Antonio Road
Palo Alto, CA 94303
Office: (650) 516-4310

Email: [email protected]

Website: www.scilexholding.com

SEMDEXA™ (SP-102) is a trademark owned by Semnur Pharmaceuticals, Inc., a wholly-owned subsidiary of Scilex Holding Company. A proprietary name review by the FDA is planned.

ZTlido® is a registered trademark owned by Scilex Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company.

Gloperba® is the subject of an exclusive, transferable license to use the registered trademark by Scilex Holding Company.

ELYXYB^TM is the subject of an exclusive, transferable license to use the trademark by Scilex Holding Company.

All other trademarks are the property of their respective owners.

© 2023 Scilex Holding Company All Rights Reserved.

BOSTON, July 05, 2023 (GLOBE NEWSWIRE) — Today, Flywire Corporation (Flywire) (Nasdaq: FLYW), a global payments enablement and software company, announced that its second quarter 2023 financial results will be released after market close on Tuesday, August 8, 2023. Flywire will host a conference call to discuss its second quarter 2023 financial results at 5:30pm ET the same day. Hosting the call will be Mike Massaro, CEO, Rob Orgel, President and COO, and Mike Ellis, CFO.

The conference call will be webcast live from Flywire’s investor relations website at https://ir.flywire.com/. A replay will be available on the investor relations website following the call.

About Flywire

Flywire (Nasdaq: FLYW) is a global payments enablement and software company. Flywire combines its proprietary global payments network, next-gen payments platform and vertical-specific software to deliver the most important and complex payments for clients and their customers.

Flywire leverages its vertical-specific software and payments technology to deeply embed within the existing A/R workflows for its clients across the education, healthcare and travel vertical markets, as well as in key B2B industries. Flywire also integrates with leading ERP systems, so organizations can optimize the payment experience for their customers while eliminating operational challenges.

Flywire supports 3,300 + clients with diverse payment methods in more than 140 currencies across 240 countries and territories around the world. Flywire is headquartered in Boston, MA, USA with global offices. For more information, visit www.flywire.com. Follow Flywire on Twitter, LinkedIn and Facebook.

Contacts

Investor Relations:

Akil Hollis

[email protected]

Media:

Sarah King

[email protected]

Prosek Partners

[email protected]

WASHINGTON, July 05, 2023 (GLOBE NEWSWIRE) — Impact Observatory, a leader in AI-powered global mapping and monitoring, today announced it has entered into a partnership with Planet Labs PBC (NYSE: PL), a leading provider of daily data and insights about the world. The partnership uses AI-powered analytics to monitor land cover and land use (LULC) on top of Planet’s high-frequency, medium- and high-resolution satellite data. Automated analytics are core to helping customers better understand changes and anticipate threats at previously unobtainable speed and scale.

“The world is changing rapidly. Every day, cities develop, crops are grown, forests are managed, and yet unsustainable resource usage and natural disasters put the whole system at risk. This greatly impacts society’s choices about the infrastructure, food systems, water supplies, and natural resources that we all depend on,” said Steve Brumby, Co-founder and CEO of Impact Observatory. “With AI-powered on-demand monitoring from Impact Observatory using best-in-class PlanetScope imagery, customers get access to accurate, near real-time geospatial insights to support security, environmental and resource mapping. Monitoring land-use change based on recent trends and historical patterns enables decision makers with the detailed warnings they need to respond to climate-crisis threats to communities, infrastructure, and natural resources.”

With this partnership, customers experience high quality space-based global mapping and monitoring benefits, when compared to existing public satellite imagery solutions, including:

• 10x increase in spatial resolution: PlanetScope’s 3.5m spatial resolution enables customers to classify features in built areas such as roads, buildings, small areas of vegetation, and small bodies of water.
• 5x increase in temporal resolution: PlanetScope’s daily, global revisit allows us to see the temporary features of our living world, such as small, seasonal bodies of water and flood water that aren’t visible in weekly imagery available from public satellite data. It also allows us to monitor changes more quickly and at earlier stages, such as forest losses due to wildfire, impacts of flooding, start of new construction, and damage due to conflict.
• Annual and seasonal classification: Classify 15+ land-cover categories, both annually and seasonally, create maps up to today, create metrics, and identify areas of change.

Impact Observatory’s IO Monitor service enables government leaders to monitor the entire world in near real-time without relying solely on national assets. Leaders in governments, NGOs, finance and industry need trustworthy, actionable information about the changing world to understand opportunities, identify threats, and measure the impacts of actions. IO Monitor coupled with PlanetScope imagery meets this need with timely, up-to-date maps at previously unobtainable scale.

Impact Observatory turns millions of satellite images into maps that label every pixel into one of nine categories of major LULC. Since the release of their first global map in June 2021, Impact Observatory has received over 1,000,000 visitors accessing and downloading our annual maps via Esri Living Atlas, Microsoft Planetary Computer, and the AWS Registry of Open Data.

To learn more about Impact Observatory’s maps on-demand, please visit the IO Monitor site here. For additional information on large-scale discounts, contact Impact Observatory’s sales team at [email protected].

Supporting Resources

• 
  Impact Observatory website
  
• 
  Impact Observatory maps on-demand
  
• 
  Impact Observatory blog and news
  
• 
  Esri, powered by Impact Observatory, high resolution map of the world
  
• 
  Follow us on Twitter
  
• 
  Join us on LinkedIn
  

About Impact Observatory

Impact Observatory is a mission-driven technology company bringing artificial intelligence (AI) powered algorithms and on-demand data to sustainability and environmental risk analysis for governments, non-profit organizations, companies, and markets. Founded in 2020 in Washington, DC, Impact Observatory’s goal is to empower global decision-makers to be planetary superheroes, with the timely, actionable science-based insights they need to succeed. Visit us at impactobservatory.com.

Media Contact

Kelly Hall
Offleash PR for Impact Observatory
[email protected]